➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
Johnson and Johnson
Merck
Boehringer Ingelheim

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

« Back to Dashboard

All Clinical Trials for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02397096 Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) Recruiting Merck Sharp & Dohme Corp. Phase 3 2015-06-01 The study will evaluate the safety and efficacy of a switch to MK-1439A (MK-1439 [doravirine] plus lamivudine and tenofovir disoproxil fumarate) in HIV-1-infected participants virologically suppressed on a protocol-specified antiretroviral regimen. The primary hypothesis is that a switch to MK-1439A will be non-inferior to continuation of the regimen at Screening for 24 weeks, as assessed by the proportion of participants maintaining HIV-1 ribonucleic acid (RNA) <50 copies/mL. The Base Study will last up to 50 weeks. An optional Extension Study will evaluate long-term efficacy and safety of the switch to MK-1439A for an additional 2 years.
NCT03332095 Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Phase 1/Phase 2 2018-03-01 The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in HIV-1-infected children and adolescents.
NCT04097925 Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals Not yet recruiting Hospital Universitari de Bellvitge Phase 2 2019-09-01 This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.
NCT04097925 Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals Not yet recruiting Institut d'Investigació Biomèdica de Bellvitge Phase 2 2019-09-01 This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.
NCT04097925 Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals Not yet recruiting Fundacio Lluita Contra la SIDA Phase 2 2019-09-01 This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.
NCT04233372 Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study Not yet recruiting Dr. Josep Mallolas Phase 4 2020-02-15 Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Intervention Trials
HIV-1-infection 3
Hiv 2
HIV Infections 1
Weight Gain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Intervention Trials
Weight Gain 1
Body Weight 1
HIV Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Location Trials
United States 16
Spain 3
France 2
South Africa 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Location Trials
Texas 1
Pennsylvania 1
North Carolina 1
New Mexico 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Sponsor Trials
Willem Daniel Francois Venter 2
Hospital Universitari de Bellvitge 1
Merck Canada Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
Sponsor Trials
Other 8
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Medtronic
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.